Pluri (NASDAQ:PLUR – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.
Insider & Institutional Ownership
16.6% of Pluri shares are held by institutional investors. 43.2% of Pluri shares are held by insiders. Comparatively, 1.7% of MDxHealth shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Pluri and MDxHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pluri | -2,344.59% | N/A | -82.71% |
| MDxHealth | -33.46% | N/A | -24.25% |
Volatility and Risk
Analyst Recommendations
This is a summary of recent ratings and target prices for Pluri and MDxHealth, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pluri | 1 | 0 | 0 | 0 | 1.00 |
| MDxHealth | 1 | 4 | 1 | 0 | 2.00 |
MDxHealth has a consensus price target of $1.33, indicating a potential upside of 825.28%. Given MDxHealth’s stronger consensus rating and higher possible upside, analysts clearly believe MDxHealth is more favorable than Pluri.
Earnings and Valuation
This table compares Pluri and MDxHealth”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pluri | $1.02 million | 12.98 | -$23.82 million | ($2.45) | -0.43 |
| MDxHealth | $107.88 million | 0.07 | -$33.52 million | ($0.72) | -0.20 |
Pluri has higher earnings, but lower revenue than MDxHealth. Pluri is trading at a lower price-to-earnings ratio than MDxHealth, indicating that it is currently the more affordable of the two stocks.
Summary
MDxHealth beats Pluri on 9 of the 13 factors compared between the two stocks.
About Pluri
Pluri Inc. is a biotechnology company developing cell-based products and technologies for applications in human health, food production and other industries. The company’s platform uses three-dimensional cell expansion technology designed to grow cells at commercial scale without genetic modification. Pluri’s health-related research has historically focused on placenta-derived, off-the-shelf cell therapies, including its PLX product candidates, which have been investigated for potential use in conditions involving inflammation, tissue damage and impaired blood flow.
About MDxHealth
MDxHealth SA (NASDAQ: MDXH) is a molecular diagnostics company focused on helping physicians make more informed decisions in cancer care. The company develops and commercializes genomic and epigenetic tests designed to support cancer detection, diagnosis, prognosis and treatment planning. MDxHealth’s portfolio has primarily centered on prostate cancer. Its ConfirmMDx test analyzes prostate tissue to help identify patients who may have clinically significant cancer despite an initially negative biopsy, while SelectMDx is a urine-based test intended to help assess the likelihood of clinically significant prostate cancer and guide decisions about biopsy.
Receive News & Ratings for Pluri Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pluri and related companies with MarketBeat.com's FREE daily email newsletter.
